head-icon1.svgMeet us at an upcoming event
head-icon2.svgIn Stock. Ready to Ship
languageEN
languageEN
icon-arrow-g
counsellingContact Us
languageEN
languageEN
icon-arrow-g

background-image

Oncology

Creating Translationally Relevant Models for Immunotherapy Research: A Closer Look at Humanized FcgR Mice

Speaker: Zhiying Li, PhD


GemPharmatech has created a unique and translationally relevant humanized Fc gamma receptor (hFcgR) mouse model to advance immunotherapy drug development. FcgRs play a vital role in how monoclonal antibodies (mAbs) activate and promote various immune responses (e.g., the antibody-dependent cellular cytotoxicity (ADCC) mechanism, antibody-dependent cellular phagocytosis (ADCP)) in a tumor microenvironment. Another immunotherapy drug development approach being investigated by oncology researchers is blocking FcgRs with antagonists to minimize resistance and increase activity of mAbs. Our hFcgR mice are created by replacing the endogenous murine FcgR genes (Fcgr1, Fcgr2b, Fcgr3, Fcgr4) with the human FcgR genes (FCGR1, FCGR2A, FCGR2B, FCGR2C, FCGR3A, FCGR3B). During this webinar our experts will discuss:

  • The role of FcgRs in innate immunity

  • The differences between murine and human FcgRs

  • The need for more translationally relevant animal models that recapitulate the human condition

  • How our hFcgR mouse model can accelerate and improve your immunotherapy drug development for cancer


Watch Nowarrow-right-warrow-right-g
Prevarrow-right-warrow-right-g

Recommended for You

More information about blogs

Webinar 490X326 (1).pngmask

Upcoming

Selecting the Right Humanized Mouse Model for Immuno-Oncology Programs: A Practical Guide to Improving Translational Success

Selecting the right humanized mouse model is one of the most consequential decisions in immuno-oncology (IO) drug development. The wrong model can mask safety liabilities, inflate efficacy estimates, and weaken the data supporting regulatory submissions. Join GemPharmatech for a data-driven webinar on how strategic humanized mouse model selection strengthens preclinical decision-making, sharpens translational relevance, and supports IND-enabling studies.

meetingDate2026-07-30 00:00:00

meetingDuration11:00 AM ET

moderatorXinjie Lian

Register Now arrow-right-warrow-right-g
Webinar 454X302 .pngmask

On-Demand

Applications of Genetically Engineered Mouse Models for Hypertrophic Cardiomyopathy Research

Hypertrophic cardiomyopathy (HCM) is a prevalent and genetically heterogeneous cardiovascular disorder, with approximately 55% of familial cases linked to mutations in sarcomeric genes. To enable mechanistic and therapeutic studies, GemPharmatech has successfully developed two HCM mouse models: the Mybpc3 knockout (KO) and the Myh6 R404Q (point mutation) strains.

meetingDate2026-06-25 00:00:00

meetingDuration11:00 AM ET

moderatorYue Shen, Ph.D.

Watch Now arrow-right-warrow-right-g
undefined.pngmask

On-Demand

Overcoming ADC Resistance: Construction and Preclinical Applications of Enhertu-Resistant Models

Antibody-drug conjugates (ADCs), particularly the HER2-targeting Enhertu (DS-8201), have revolutionized targeted cancer therapy. Despite their clinical success, drug resistance remains a major hurdle limiting long-term therapeutic benefits. To address this challenge, GemPharmatech has developed multiple ADC resistance models, including a HER2-positive JIMT-1 breast cancer xenograft (CDX) model with acquired resistance to Enhertu, and a primary Enhertu-resistant HER2-positive lung cancer model from our patient-derived xenograft (PDX) library. Join us to explore how these Enhertu-resistant models serve as translational tools to elucidate resistance mechanisms and evaluate novel therapeutic strategies.

meetingDate2026-04-14 00:00:00

meetingDuration11:00 AM ET

moderatorShiying Guo, Ph.D.

Watch Now arrow-right-warrow-right-g
arrow-right-garrow-right-w
arrow-right-garrow-right-w

background-image

Find Models

Contact Our Teamarrow-right-garrow-right-w
Request Quotearrow-right-garrow-right-w

Watch On-Demand Webinar

First Name*

Last Name*

Organization*

Email*

Country/Region*

Select Country/Region

State/Province*

City

Research Focus

Submitarrowarrow

Submit Inquiry

First Name*

Last Name*

Organization*

Email*

Country/Region*

Select Country/Region

State/Province*

City

Area of interest*

Select Area of Interest

Research Focus

Additional Info

Submitarrowarrow

Contact Us

First Name*

Last Name*

Organization*

Email*

Country/Region*

Select Country/Region

State/Province*

City

Area of interest*

Select Area of Interest

Research Focus

How did you hear about us*

Select a source

Leave us a message

Submitarrowarrow

Schedule a Meeting

Let us know which event you're attending and we'd be happy to connect with you.

First Name*

Last Name*

Organization*

Email*

Country/Region*

Select Country/Region

State/Province*

City

Area of interest*

Select Area of Interest

Research Focus

How did you hear about us*

Select a source

Leave us a message

Submitarrowarrow

Download

First Name*

Last Name*

Organization*

Email*

Country/Region*

Select Country/Region

State/Province*

City

Research Focus

Submitarrowarrow

Download

First Name*

Last Name*

Organization*

Email*

Country/Region*

Select Country/Region

State/Province*

City

Research Focus

Submitarrowarrow

Watch On-Demand Webinar

First Name*

Last Name*

Organization*

Email*

Country/Region

Select Country/Region

State/Province*

City

Research Focus

Submitarrowarrow

Newsletter Signup

First Name*

Last Name*

Organization*

Email*

Country/Region*

Select Country/Region

Area of interest*

Select Area of Interest

Research Focus

Submitarrowarrow